#United States #New York #Levi & Korsinsky #Fractyl Health #NASDAQ:GUTS

Recent Updates on Fractyl Health, Inc. Securities Class Action

As concerns about corporate governance rise, Fractyl Health, Inc. finds itself at the center of a significant securities class action lawsuit. This lawsuit draws attention to allegations of misrepresentation in the efficacy data of the Revita DMR System, a product critical to the company's portfolio. Investors are urged to pay close attention as the deadline for lead plaintiff applications approaches on October 20, 2026.

Background on Fractyl Health, Inc.

Fractyl Health, listed under NASDAQ as GUTS, specializes in developing therapies aimed at combating metabolic diseases, with a focus on obesity and diabetes. The company’s flagship product, the Revita DMR, is designed to improve weight management outcomes. However, uncertainty surrounding the data supporting its efficacy has caused a significant decline in investor confidence.

Allegations of Misrepresentation

The class action against Fractyl Health is premised on the assertion that key executives, including Co-Founder and CEO Harith Rajagopalan and former CFO Lisa A. Davidson, may have knowingly issued false statements about the clinical outcomes of Revita. These misstatements reportedly led to a staggering approximate value loss of 74.86% over just two trading days.

The lawsuit highlights key sections of the Sarbanes-Oxley Act, particularly Sections 302 and 906, which obligate executives to ensure their company’s public disclosures are accurate and complete. The executives allegedly failed to disclose material information regarding operational issues at a key clinical site, thus misleading investors about the real effectiveness of the Revita DMR.

Understanding the Current Situation

On January 28, 2026, Fractyl Health shares closed at a reference price of $1.83. Following alarming disclosures concerning the company's products, the stock price plummeted to $0.46 within two days. The timing of these disclosures has escalated the urgency for shareholders to evaluate their positions and action accordingly.

Joseph E. Levi, an attorney from Levi & Korsinsky LLP, has publicly stated, "Corporate officers have a duty to ensure their companies' public statements are accurate and complete," emphasizing the implications their failures could have on investors.

What You Need to Do as a Shareholder

Investors who purchased Fractyl securities between January 13, 2025, and January 29, 2026, may be eligible to recover their losses. To facilitate this process, shareholders need to gather relevant documentation, including brokerage records that detail their purchase dates, quantities of shares, and prices paid.

For those interested in taking action, Levi & Korsinsky offers a no-cost consultation to evaluate potential recovery options. Even shareholders who have sold their shares during the class period may still be eligible for claims, underscoring the significance of the current situation.

This impending deadline serves as a crucial point for investors to act. Failing to submit your application by October 20, 2026, may forfeit your opportunity to lead the class action process.

Joining the Legal Action

The class action lawsuit has been filed in the United States District Court for the Southern District of New York, affirming the necessity for diligent oversight and representation of affected investors. Investors are encouraged to participate in this legal action to ensure that their voices and interests are adequately represented.

In conclusion, the Fractyl Health lawsuit presents a complex narrative of corporate responsibility and investor rights. As the deadline looms, shareholders must act swiftly to safeguard their interests. For more details or to start the process, contact Levi & Korsinsky LLP at (212) 363-7500 or visit their website for further information on this significant investor alert.